A clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions. Our lead product candidate, DMT310, is the first product candidate being developed from our Spongilla technology platform. DMT310 is of a once-weekly topical product derived from a naturally sourced freshwater sponge with multiple components.
Lead Underwriter
Maxim Group, LLC
Co-Managers
Brookline Capital Markets, a division of Arcadia Securities, LLC
